NEW YORK—The Alzheimer’s Association International Conference 2016 saw Anavex Life Sciences Corp. present data from the first of two posters regarding ANAVEX 2-73. The first poster reported the evaluation of a maximum tolerated dose for the drug as a primary endpoint of the Phase 2a study in patients with mild-to-moderate Alzheimer’s disease, as well as other clinical safety data. Among these were some positive unexpected therapeutic responses, including improved mood and social engagement and increased independent activities through 31 weeks. ANAVEX 2-73 continues to present a favorable profile in terms of adverse events, and dose-response analysis indicated a cognitive benefit associated with the drug, as both MMSE and EEG/ERP saw significant improvement at 5 weeks of treatment.

 

“We are encouraged by these new results, which provide us with valuable knowledge about ANAVEX 2-73 and allow us to proceed methodically in the development of ANAVEX 2-73,” said Anavex President and CEO Dr. Christopher U. Missling.